Focus on ivabradine: A new heart rate-controlling drug

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 2, 2009, Pages 107-113

  Riccioni, Graziano ^a  

^a SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

Author keywords

Arrhythmia; Cardiovascular disease; Chronic stable angina; Current; Heart rate; Ivabradine

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; HYDRALAZINE; IVABRADINE; LANSOPRAZOLE; METOPROLOL; NITRIC ACID DERIVATIVE; OMEPRAZOLE; PLACEBO; PROPRANOLOL; VERAPAMIL; BENZAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT;

ARTICLE; ATHEROSCLEROSIS; BRADYCARDIA; CHRONIC DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG ACTIVITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART RATE; HUMAN; MORBIDITY; MORTALITY; POSTURAL TACHYCARDIA SYNDROME; QT PROLONGATION; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; SINUS RHYTHM; STABLE ANGINA PECTORIS; TACHYCARDIA; VISUAL DISORDER; ANGINA PECTORIS; ANIMAL; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

ADRENERGIC BETA-ANTAGONISTS; ANGINA PECTORIS; ANIMALS; BENZAZEPINES; CARDIOVASCULAR AGENTS; CLINICAL TRIALS AS TOPIC; HEART RATE; HUMANS; RISK FACTORS; VISION DISORDERS;

EID: 64749100841     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.7.2.107     Document Type: Article

References (54)

1. DiFrancesco D. Characterization of single pacemaker channels in cardiac sino-atrial node cells. Nature 324, 470-473 (1986).
2. f) to generation of spontaneous activity in rabbit sino-atrial node myocytes. J. Physiol. 34, 23-40 (1991).
3. f inhibition: a novel mechanism of action. Eur. Heart. J. 5, 19-25 (2003).
4. Bucchi A, Barbuti A, Baruscotti M et al. Heart rate reduction via selective 'funny' channel blockers. Curr. Opin. Pharmacol. 7, 208-213 (2007).
5. Thollon C, Cambarrat C, Vian J et al. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br. J. Pharmacol. 112, 37-42 (1994).
6. Bois P, Bescond J, Renaudon B et al. Mode of action of bradycardic agent, S16257, on ionic currents of rabbit sinoatrial node cells. Br. J. Pharmacol. 118, 1051-1057 (1996).
7. Gardibner SM, Kemp PA, March JE et al. Acute and chronic cardiac and regional haemodynamic effects of the novel bradycardic agent, S16257, in conscious rats. Br. J. Pharmacol. 115, 579-586 (1995).
8. Simon L, Ghaleh B, Puybasset L et al. Coronary and haemodynamic effects of S16257, a new bradycardic agents, in resting and exercising conscious dogs. J. Pharmacol. Exp. Ther. 275, 579-586 (1995).
9. Ragueneau I, Laveille C, Jochemsen R et al. Pharmacokinetic-pharmacodynamic modelling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin. Pharmacol. Ther. 64, 192-203 (1998).
10. f inhibitor, in stable angina: a randomized, double-blinded, multicentered, placebo-controlled trial. Circulation 107, 817-823 (2003).
11. Ludwig A, Zong X, Jeglitsch M et al. A family of hyperpolarization-activated mammalian cation channels. Nature 393, 587-591 (1998).
12. Santoro B, Liu DT, Yao H et al. Identification of a gene encoding a hyperpolarization-activated pacemaker channel of brain. Cell 93, 717-729 (1998).
13. Ishii TM, Takano M, Xie LH et al. Molecular characterization of the hyperpolarization-activated cation channel in rabbit heart sinoatrial node. J. Biol. Chem. 274, 12835-12839 (1999).
14. Komajda M, Follath F, Swedberg K et al. The Euro Heart Failure Survey Programme: a survey on the quality of care among patients with heart failure in Europe. Eur. Heart. 24, 464-474 (2003).
15. Ludwig A, Zong X, Hofmann F et al. Structure and function of cardiac pacemaker channels. Cell. Physiol. Biochem. 9, 179-186 (1999).
16. Baruscotti M, DiFrancesco D. Pacemaker channels. Ann. NY Acad. Sci. 1015, 111-121 (2004).
17. f channels by ivabradine. J. Gen. Physiol. 1230, 1-13 (2002).
18. Bois P, Guinamard R, Chemaly AE et al. Molecular regulation and pharmacology of pacemaker channels. Curr. Pharm. Des. 13, 2338-2349 (2007).
19. f inhibitor with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 64, 1757-1765 (2004).
20. Camm AJ, Lau CP. Electrophysiological effects on a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs 4, 83-89 (2003).
21. Joannides R. Moore N, Iacob M et al. Comparative effects of ivabradine, a selective heart rate-lowering agents, and propanolol on systemic and cardiac haemodynamics at rest during exercise. Br. J. Pharmacol. 61, 127-137 (2006).
22. f inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 100, 149-155 (2003).
23. De Ferrari GM, Mazzuero A, Agnesina L et al. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur. J. Heart. Fail. 10, 550-555 (2008).
24. f inhibitor, compared with atenolol in patients with chronic stable angina. Eur. Heart. J. 26, 2529-2536 (2005).
25. f inhibition in the management of stable angina pectoris and other cardiovascular diseases. Drugs Today 44, 171-181 (2008).
26. f current inhibitor in the treatment of stable angina. Rec. Pat. Cardiovasc. Drug Discov. 1, 277-282 (2006).
27. f improves symptoms in severe dilated cardiomyopathy. Clin. Res. Cardiol. 96, 243-246 (2007).
28. f current inhibition by ivabradine. Drugs 67(Suppl. 2), 35-41 (2007).
29. Diaz A, Tardif JC. Heart rate slowing versus other pharmacological antianginal strategies. Adv. Cardiol. 43, 65-78 (2006).
30. f inhibition: new perspectives for the treatment of stable angina. Expert Opin. Pharmacother. 7, 1211-1220 (2006).
31. Ferrari R, Cargnoni A, Ceconi C. Anti-ischaemic effect of ivabradine. Pharmacol. Res. 53, 435-439 (2006).
32. Ruzyllo W, Tendera M, Ford I et al. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris; a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs 67, 393-405 (2007).
33. López-Bescós L, Filipova S, Martos R. Long-term safety and efficacy of ivabradine in patients with chronic stable angina. Cardiology 108, 387-396 (2007).
34. f current inhibitor ivabradine in patients with stable angina pectoris receiving β-blockers. A 4-month randomised, double-blind, multicenter trial. Eur. Heart. J. 29(Abstract Suppl.), 386 (2008).
35. f-inhibitor ivabradine in lowering of rate of development of cardiac complications after carotid endarterectomy. Kardiologiia 48, 56-59 (2008).
36. Babu KS, Gadzik F, Holgate ST. Absence of respiratory effects with ivabradine in patients with asthma. Br J. Clin. Pharmacol. 66, 96-101 (2008).
37. f current inhibitor. Am. J. Therapeutics. 15, 461-473 (2008).
38. Mulder P, Thuillez C. Heart rate slowing for myocardial dysfunction/ heart failure. Adv. Cardiol. 43, 97-105 (2006).
39. Wikstrand J, Berglund G, Hedblad B et al. Antiatherosclerotic effects of β-blockers. Am. J. Cardiol. 91, 25-29 (2003).
40. Hedbald B, Wikstrand J, Janzon L et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the β-blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 103, 1721-1726 (2001).
41. Wiklund O, Kulthe J, Wikstrand J et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 33, 572-577 (2002).
42. Custodis F, Baumhäkel M, Schlimmer N et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 117, 2377-2387 (2008).
43. Triggle CR. Defying the economists: a decrease in heart rate improves not only cardiac but also endothelial function. Br. J. Pharmacol. 154, 727-728 (2008).
44. Drouin A, Gendron ME, Thorin E et al. Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. Br. J. Pharmacol. 154, 749-757 (2008).
45. Yusuf S, Camm AJ. Sinus tachyarrhythmias and the specific bradycardic agents: a marriage made in heaven? J. Cardiovasc. Pharmacol. Ther. 8, 89-105 (2003).
46. Ewan V, Norton M, Newton JL. Symptom improvement in postural orthostatic tachycardia syndrome with the sinus node blocker ivabradine. Europace 9, 1202 (2007).
47. Schulze V, Steiner S, Hennersdorf M et al. Ivabradine as an alternative therapeutic trial in the therapy of inappropriate sinus tachycardia: a case report. Cardiology 110, 206-208 (2008).
48. fUL): a subgroup analysis of a randomised controlled trial. Lancet 372, 817-821 (2008).
49. fUL): a randomised, double-blind, placebo-controlled trial. Lancet 372, 807-816 (2008).
50. Cervetto L, Demontis GC, Gargini C. Cellular mechanisms underlying the pharmacological induction of phosphenes. Br. J. Pharmacol. 150, 383-390 (2007).
51. f current inhibitor ivabradine: safety considerations. Adv. Cardiol. 43, 79-96 (2006).
52. f inhibition with ivabradine: eiectrophysiological effects and safety. Drug. Saf. 31, 95-107 (2008).
53. Portolés A, Calvo A, Terleira A et al. Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. J. Clin. Pharmacol. 46, 1195-1203 (2006).
54. Portolés A, Terleira A, Calvo A et al. Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. J. Clin. Pharmacol. 46, 1188-1194 (2006).